A study revealed that most patients with generalized myasthenia gravis (gMG) treated in routine care did not meet the criteria for phase 3 clinical trials. Specifically, 89.5% of patients and 95% of clinic visits were ineligible, primarily due to low Myasthenia Gravis Activities of Daily Living scores and recent medication changes. Researchers suggest the need for broader inclusion criteria in clinical trials to make results more applicable to a diverse patient population, highlighting the limitations of current trial criteria in capturing a representative patient sample.
Reference: Ciccone I. Majority of Patients With Generalized Myasthenia Gravis Fail to Meet Clinical Trial Criteria. NeurologyLive. Updated November 7, 2023. Accessed November 29, 2023.
